Glycopeptide Antibiotics Market Size In 2026: Growth Outlook And Forecast Through 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Glycopeptide Antibiotics Market CAGR Outlook And Future Development
The glycopeptide antibiotics market has experienced substantial growth in recent years. This market is expected to expand from $3.78 billion in 2025 to $4.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. Historically, this growth can be attributed to factors such as an increase in hospital-acquired infections, the widespread application of vancomycin as a standard therapeutic option, the rising prevalence of gram-positive bacterial infections, the limited availability of alternative antibiotics, and the ongoing expansion of inpatient healthcare infrastructure.
The glycopeptide antibiotics market size is anticipated to experience substantial growth over the next few years, projecting to reach $5.89 billion in 2030 with a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period can be attributed to the rise in multidrug-resistant pathogens, the increasing uptake of long-acting glycopeptides, a growing demand for outpatient and home-based antibiotic therapies, ongoing research and development in next-generation glycopeptides, and increasing global healthcare expenditure. Prominent trends for the forecast period include an escalating reliance on glycopeptides for resistant infections, an expansion of the lipoglycopeptide antibiotics portfolio, increased hospital utilization of intravenous glycopeptides, an enhanced focus on optimized dosing and therapeutic monitoring, and broader adoption in severe gram-positive infections.
Get A Free Sample Report With In-Depth Market Insights:
Glycopeptide Antibiotics Market Growth Catalysts And Demand Drivers
The increasing incidence of gram-positive infections is projected to drive the expansion of the glycopeptide antibiotic market in the upcoming years. Gram-positive infections are caused by specific gram-positive bacteria such as *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Streptococcus pyogenes*. Glycopeptide antibiotics effectively combat many gram-positive bacteria by targeting their cell wall formation through a unique mechanism. As an illustration, in June 2023, the “Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023” from the UK Health Security Agency, a UK-based government body focused on public health and infectious-disease protection, indicated a sharp increase in invasive Group A Streptococcus (iGAS) activity, with 509 laboratory-confirmed iGAS notifications recorded by week 46 of 2023, including a weekly high of 73 cases. This surge highlights a growing burden from infectious diseases, thereby escalating the demand for effective antimicrobial therapies throughout the healthcare system. Thus, the rising prevalence of gram-positive infections is a significant driver for the glycopeptide antibiotic market.
Glycopeptide Antibiotics Market Breakdown By Product Type And Application
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation, Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Glycopeptide and Lipoglycopeptide Antibiotics
Glycopeptide Antibiotics Market Trends Shaping Long-Term Demand
Leading companies in the glycopeptide antibiotics market are concentrating on developing innovative products, such as novel glycopeptide scaffolds, to achieve a competitive edge. These novel glycopeptide scaffolds represent structurally distinct antibiotic backbones, derived through advanced biosynthetic methods or natural-product mining techniques. For instance, in May 2025, a Chinese-European research consortium, a China-based cross-continental expertise, unveiled Saarvienin A, a newly discovered glycopeptide featuring a halogenated peptide core, an unusual ureido linkage, and five distinct sugar or aminosugar units. Saarvienin A does not bind the traditional cell-wall target of other glycopeptides, indicating a potentially novel mechanism, and exhibits potent in vitro activity against resistant Gram-positive pathogens such as MRSA and vancomycin-resistant Enterococcus. While this innovation marks a significant step forward in addressing antibiotic resistance, it faces challenges including clinical translation, optimization for safety, and the scale-up of production.
Glycopeptide Antibiotics Market Company Landscape And Competitive Strategy
Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
View The Full Glycopeptide Antibiotics Market Report:
Glycopeptide Antibiotics Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
